Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Fate, Stemgent platform reprograms mature cells as stem cells

Executive Summary

Fate Therapeutics (stem cell biology aimed at modulating cell fate; has a late-preclinical candidate in hematopoietic reconstitution) and Stemgent (reagents for stem cell generation) are creating a program called Catalyst that will offer pharma and biotech clients a platform for drug discovery and development. The technique creates iPS cells--induced pluripotent stem cells--and then re-differentiates them into distinct cell types.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register